CN1314677C - Acetyl salicyl puerarin derivatives and preparation method and use thereof - Google Patents
Acetyl salicyl puerarin derivatives and preparation method and use thereof Download PDFInfo
- Publication number
- CN1314677C CN1314677C CNB2004100360709A CN200410036070A CN1314677C CN 1314677 C CN1314677 C CN 1314677C CN B2004100360709 A CNB2004100360709 A CN B2004100360709A CN 200410036070 A CN200410036070 A CN 200410036070A CN 1314677 C CN1314677 C CN 1314677C
- Authority
- CN
- China
- Prior art keywords
- puerarin
- acetyl
- preparation
- meant
- salicyloyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a compound acetyl salicyl puerarin derivant of a general formula (I). The present invention also relates to a preparation method of the compound and the application of the acetyl salicyl puerarin derivant in the preparation of medicine for resisting platelet aggregation. The class compound has obvious inhibiting effect of dose dependent to platelet aggregation rection outside human bodies and has good application prospects on the aspect of the treatment of cardio-cerebral vascular diseases.
Description
Technical field
The invention belongs to medical technical field, relate generally to the derivative and preparation method thereof and application of puerarin, relate in particular to acetyl salicyloyl puerarin derivate and preparation thereof and application.
Background technology
Puerarin is the effective diseases of cardiovascular and cerebrovascular systems medicine of a kind of natural low toxicity, pharmacological action is extensive, coronary heart disease, stenocardia, cerebral infarction, ischemic cerebrovascular disease have been used for the treatment of clinically, improve platelet function, reduce (pharmacological action of Ou Ming flood puerarin and clinical application pharmacy construction 2000,9 (12): 59-60) such as diabetes trace white protein, diabetes and nephropathy preventing.But puerarin oral organism-absorbing availability is relatively poor, and the application of oral dosage form is restricted, and the injection liquid formulation of clinical main use puerarin is used for convenient, need improve puerarin solvability and bioavailability.The pertinent literature report mainly is to carry out structural modification or adopts special form at present.Yang Ruolin etc. once to puerarin carried out a series ofly methylating, the derivatize transformation of methoxyl group, sec.-propyl, benzoyl, trityl etc., show that tritylation and acetylize person show blood flow increasing in the compound after resulting structures is modified but carry out the test of lagophthalmos volume of blood flow.(Yang Ruolin, the preparation of puerarin derivates such as Li Na and active China Medicine University journal 1999,30 (2) thereof: 81-85).The structural modification of report to other flavonoid compound also arranged in addition, Wang Xiaoli attempts the 7-flavonol is synthesized ester (Wang Xiaoli with forulic acid, nicotinic acid, Chlorophibrinic Acid respectively, Xu Mingxia, thank to the synthetic West China pharmaceutical journal 1999,14 (5-6) of beneficial agricultural 7-Hydroxyflavone derivatives: 309-314).Trials such as YanBing Shuan are parent with the 7-flavonol of B endless belt different substituents, and to thromboxane A
2Synthetic enzyme has stronger inhibiting imidazoles and becomes ester (YanBing Shuan, Sun Tiemin, the force synthetic Chinese pharmaceutical chemistry magazine 1994,4 (1) of minister in ancient times 7-acetyl bigcatkin willow acyloxy flavone derivative: the 36-40 that shakes with acetylsalicylic acid; YanBing Shuan, Sun Tiemin, the shake synthetic Chinese pharmaceutical chemistry magazine 1995,5 (1) of minister in ancient times 7-(1-imidazoles)-alkoxyl group flavone derivative of force: 44-46).
Although have in the prior art and many puerarin carried out a series of derivatize transformations,, by retrieval, have not yet to see puerarin is carried out structural modification with acetylsalicylic acid, the report of preparation acetyl salicyloyl puerarin and derivative thereof.
Summary of the invention
Deficiency at the prior art existence, one of the problem to be solved in the present invention is relatively poor at puerarin oral organism-absorbing availability, the clinical present situation that only has injection to use provides a kind of puerarin structural modification derivative---acetyl salicyloyl puerarin and derivative thereof and its preparation method; Two of the problem to be solved in the present invention provides the application of acetyl salicyloyl puerarin derivate in the medicine of preparation platelet aggregation-against.
Acetyl salicyloyl puerarin derivate of the present invention is represented with following general formula (I):
Wherein:
R
1, R
2, R
3Be meant: hydrogen, ethanoyl or acetyl salicyloyl, and R
1, R
2, R
3, at least one is the acetyl salicyloyl, R
4, R
5Or R
6Be meant hydrogen.。
R wherein
1, R
2Or R
3Be meant: ethanoyl or acetyl salicyloyl; R
4, R
5Or R
6Be meant hydrogen.
R wherein
1Or R
2Be meant: ethanoyl or acetyl salicyloyl; R
3, R
4, R
5Or R
6Be meant hydrogen.
R wherein
1Or R
3Be meant: ethanoyl or acetyl salicyloyl; R
2, R
4, R
5Or R
6Be meant hydrogen.
R wherein
1Be meant the acetyl salicyloyl; R
2, R
3, R
4, R
5Or R
6Be meant hydrogen.
The preferred 7-acetyl of above-claimed cpd salicyloyl puerarin, 7-acetyl salicyloyl-4 '-ethanoyl puerarin or 7-acetyl salicyloyl-6 "-the ethanoyl puerarin.
The preparation method of compound of the present invention, this method steps is as follows:
(1) preparation of acetyl bigcatkin willow acyl chlorides: with acetylsalicylic acid and thionyl chloride by 1: 1～2 mixed in molar ratio, with the pyridine is solvent, reacts 2～3 hours in 60 ℃～80 ℃ oil baths, removes solvent under reduced pressure, get acetyl bigcatkin willow acyl chlorides, place anhydrous tetrahydro furan standby;
(2) preparation puerarin derivate: puerarin is dissolved in the alkaline anhydrous solvent, under condition of ice bath, above-mentioned acetyl bigcatkin willow acyl chlorides is pressed and puerarin 1～5: 1 mol ratio slowly joins in the alkaline anhydrous solution of puerarin, 20 ℃～35 ℃ reactions 1～2 hour, refluxed 2～3 hours, conventional filtration, concentrated, evaporate to dryness obtain acetyl salicyloyl puerarin derivate;
(3) separation and purification of puerarin derivate: adopt conventional silica gel column chromatography means, above-mentioned reaction is obtained acetyl salicyloyl puerarin derivate carry out separation and purification.
Wherein, the described alkaline anhydrous solvent of step (2) is preferably the anhydrous tetrahydro furan solvent of saturated potassium carbonate.
Wherein, the mol ratio of step (2) described acetyl bigcatkin willow acyl chlorides and puerarin preferably 2～3: 1.
The application in the medicine of preparation platelet aggregation-against of compound acetyl salicyloyl puerarin derivate of the present invention and preparation thereof.
Can be made into the above the medicine of formulation of any pharmaceutics with acetyl salicyloyl puerarin derivate of the present invention; Preferred oral preparation or injection in described formulation.
Utilizing the 7-acetyl salicyloyl puerarin of compound acetyl salicyloyl puerarin derivate of the present invention to carry out the anticoagulant activity experiment shows: outer platelet aggregation reaction has the restraining effect of the dose-dependently of highly significant to human body, has the applications well prospect aspect cardiovascular and cerebrovascular diseases.
Utilize acetyl salicyloyl puerarin derivate of the present invention; preferred 7-acetyl salicyloyl puerarin; select the turbid experimental technique of ratio of routine clinical check platelet function, observe its situation that influences the outer platelet aggregation effect of adenosine diphosphate (ADP) (ADP) inductive human body.And the antiplatelet aggregative activity of puerarin derivate and traditional antithrombotic reagent acetylsalicylic acid and the effect situation of reactant puerarin compared, with the structural modification of conclusive evidence puerarin and the dependency of drug action.The result is in the effect experiment concentration range, and outer platelet aggregation reaction has the restraining effect of the dose-dependently of highly significant to 7-acetyl salicyloyl puerarin to human body.Under the same concentrations condition, the effect of 7-acetyl salicyloyl puerarin anticoagulant is better than single with clinical antithrombotic reagent acetylsalicylic acid and puerarin significantly.7-acetyl salicyloyl puerarin, acetylsalicylic acid and puerarin suppress aggregate concentration IC to the half of vitro human platelet aggregation reaction
50Be respectively 0.91mmol.L
-1, 3.99mmol.L
-1And 3.18mmol.L
-1Compare with the puerarin of same molar ratio and the antiplatelet aggregative activity of acetylsalicylic acid mixing solutions, the anti-congregation of derivative is better than physical mixed solution, and both exist significant difference.
Acetylsalicylic acid itself is as antithrombotic reagent, and the main mechanism of action is that to hematoblastic inhibition acetylsalicylic acid is expected to produce synergy with combining of puerarin.Compound of the present invention is the principle of hybridization according to medicinal design, makes acetylsalicylic acid and puerarin be combined into the pharmaceutical composition that the ester reaction is made by acidylate.Utilize preparation method of the present invention, resulting composition is included in a series of derivatives of the hydroxyl generation acetyl bigcatkin willow acidylate on puerarin different positions, the different number, can obtain the simplification compound respectively by conventional column chromatography means.Compound of the present invention has changed the polarity and the space structure of puerarin itself, to influence the penetrating function of cytolemma water-soluble, that improve medicine of compound, the absorption of enhancing in gi tract, improve the oral administration biaavailability of puerarin, reduce the pungency of acetylsalicylic acid, reach synergistic result.
Utilizing acetyl salicyloyl puerarin derivate of the present invention to carry out the anticoagulant activity experiment shows: outer platelet aggregation reaction has the restraining effect of the dose-dependently of highly significant to human body; and restraining effect is better than single clinical antithrombotic reagent acetylsalicylic acid and puerarin with a great deal of significantly; and the physical mixture of the two, and exist significant difference.This compounds can overcome at present shortcomings such as puerarin oral organism-absorbing availability is relatively poor clinically, the acetylsalicylic acid pungency is bigger, and the stronger biological effect of performance, should have the applications well prospect aspect the preparation cardiovascular and cerebrovascular diseases medicine.
Description of drawings
Fig. 1 7-acetyl salicyloyl puerarin
1The HNMR spectrogram
Fig. 2 7-acetyl salicyloyl puerarin
13The CNMR spectrogram
Fig. 3 7-acetyl salicyloyl puerarin
1H-
1The HCOSY spectrogram
The HMQC spectrogram of Fig. 4 7-acetyl salicyloyl puerarin
The HMBC collection of illustrative plates of Fig. 5 7-acetyl salicyloyl puerarin
The MS spectrogram of Fig. 6 7-acetyl salicyloyl puerarin
The IR spectrogram of Fig. 7 7-acetyl salicyloyl puerarin
Fig. 8 7-acetyl salicyloyl-4 '-the ethanoyl puerarin
1The HNMR spectrogram
Fig. 9 7-acetyl salicyloyl-4 '-the ethanoyl puerarin
13The CNMR spectrogram
Figure 10 7-acetyl salicyloyl-4 '-the ethanoyl puerarin
1H-
1The HCOSY spectrogram
Figure 11 7-acetyl salicyloyl-4 '-the HMQC spectrogram of ethanoyl puerarin
Figure 12 7-acetyl salicyloyl-4 '-the HMBC collection of illustrative plates of ethanoyl puerarin
Figure 13 7-acetyl salicyloyl-4 '-the MS spectrogram of ethanoyl puerarin
Figure 14 7-acetyl salicyloyl-6 "-the ethanoyl puerarin
1The HNMR spectrogram
Figure 15 7-acetyl salicyloyl-6 "-the ethanoyl puerarin
13The CNMR spectrogram
Figure 16 7-acetyl salicyloyl-6 "-the MS spectrogram of ethanoyl puerarin
Embodiment
1. the preparation of acetyl salicyloyl puerarin derivate
Embodiment 1:
The acetylsalicylic acid of 9.0g (about 0.05mol) is mixed with the sulfur oxychloride of 7ml (about 0.084mol), add 4 of pyridines, oil bath slowly is warming up to 75 ℃ in 50min, isothermal reaction 2h, remove liquid under reduced pressure, add the 6ml anhydrous tetrahydro furan, airtight preservation is stand-by.4.2g puerarin (about 0.01mol) is dissolved with an amount of anhydrous tetrahydro furan, add the 5g anhydrous sodium carbonate, stirring at room 10min.Slowly drip acetyl bigcatkin willow acyl chlorides 5.5g (about 0.026mol) under the ice bath agitation condition, behind the room temperature reaction 1h, backflow 2h removes solvent under reduced pressure after the filtration.Solid is through conventional silica gel column chromatography, chloroform-methyl alcohol system gradient elution, silica gel thin-layer chromatography (CHCl
3: MeOH=8: 2,1%FeCl
3-K
3[Fe (CN)
6] colour developing of (1: 1) solution) detect, collect merging R
f=0.4～0.5 stream part, conventional concentrating, crystallization gets 7-acetyl salicyloyl puerarin 1.36g.
7-acetyl salicyloyl puerarin (structural formula is formula structure A as follows) is a white powder, molecular formula: C
30H
26O
12, molecular weight: 578.mp：195.6～196.8℃。IR v
KBrmax(cm
-1)3425(v
-OH)，1746(v
C＝O)，1633，1608(v
CC)，1515，1229，1197，1110(v
C-O-C)，1485，1435，1371(δ
-CH3)，MS m/z(％)(579.4)：579.3(100)，537.3(10)，459.4(8)，417.3(16)，399.3(4)，321.3(6)，279.3(4)，163.4(2)，121.2(2)。
1HNMR,
13CNMR,
1H-
1HCOSY, HMQC, HMBC, MS, IR spectrogram are seen accompanying drawing 1-7.
1HNMR and
13CNMR spectrum data see Table 1 and 2 respectively.
Embodiment 2:
The acetylsalicylic acid of 9.0g (about 0.05mol) is mixed with the sulfur oxychloride of 5ml, add 4 of pyridines, oil bath slowly is warming up to 60 ℃ in 50min, isothermal reaction 2h removes liquid under reduced pressure, adds the 6ml anhydrous tetrahydro furan, and airtight preservation is stand-by.10.0g puerarin (about 0.025mol) is dissolved with an amount of anhydrous tetrahydro furan, add the 5g anhydrous sodium carbonate, stirring at room 10min.Slowly drip acetyl bigcatkin willow acyl chlorides 5.5g (about 0.026mol) under the ice bath agitation condition, behind the room temperature reaction 2h, backflow 2h removes solvent under reduced pressure after the filtration.Solid is through conventional silica gel column chromatography, chloroform-methyl alcohol system gradient elution, silica gel thin-layer chromatography (CHCl
3: MeOH=8: 2,1%FeCl
3-K
3[Fe (CN)
6] colour developing of (1: 1) solution) detect, collect merging R
f=0.65～0.85 stream part, conventional concentrating, crystallization get 7-acetyl salicyloyl-4 '-ethanoyl puerarin 1.21g.
7-acetyl salicyloyl-4 '-ethanoyl puerarin (structural formula is formula structure B as follows) is white bulk crystals, molecular formula: C
32H
28O
13, molecular weight: 620, mp:141.0～143.5 ℃.MS m/z(％)：621.6(100)，515.5(10)，339.5(25)，330.6(30)，163.3(15)，131.1(17)，121.4(10)。
1HNMR,
13CNMR,
1H-
1HCOSY, HMQC, HMBC, MS spectrogram are seen accompanying drawing 8-13,
1HNMR and
13CNMR spectrum spectrum data see Table 1 and 2 respectively.
Embodiment 3:
The acetylsalicylic acid of 9g (about 0.05mol) is mixed with the sulfur oxychloride of 8ml, add 4 of pyridines, oil bath slowly is warming up to 80 ℃ in 50min, isothermal reaction 2h removes liquid under reduced pressure, adds the 6ml anhydrous tetrahydro furan, and airtight preservation is stand-by.6.2g puerarin (about 0.015mol) is dissolved with an amount of anhydrous tetrahydro furan, add the 5g anhydrous sodium carbonate, stirring at room 10min.Slowly drip acetyl bigcatkin willow acyl chlorides 5.5g (about 0.026mol) under the ice bath agitation condition, behind the room temperature reaction 1h, backflow 3h removes solvent under reduced pressure after the filtration.Solid is through conventional silica gel column chromatography, chloroform-methyl alcohol system gradient elution, silica gel thin-layer chromatography (CHCl
3: MeOH=8: 2,1%FeCl
3-K
3[Fe (CN)
6] colour developing of (1: 1) solution) detect, collect merging R
f=0.5～0.6 stream part, conventional concentrating, crystallization gets 7-acetyl salicyloyl-6 " ethanoyl puerarin 0.83g.
7-acetyl salicyloyl-6 "-ethanoyl puerarin (structural formula is the formula structure C as follows) is white bulk crystals, molecular formula: C
32H
28O
13, molecular weight: 620.mp.152.0～154.1℃。MS m/z：621.6[M+1]
+，643[M+23]
+，659[M+39]
+，459.6[458+1]
+。
1HNMR,
13CNMR, MS spectrogram are seen accompanying drawing 14-16.
1HNMR and
13CNMR spectrum data see Table 1 and 2 respectively.
Table 1 compound (A, B, C)
1HNMR data (ppm)
| H | A | B * | C |
| H-2 H-5 H-6 H-2’，6’ H-3’，5’ H-1” H-2” H-3” H-4” H-5” H 2-6” H-3”’ H-4” H-5” H-6” -CH 3 | 8.32s 8.26s 7.33 7.52d 6.92d 5.14d 4.09 3.56 3.16 3.41 3.63，3.27 7.31 7.78 7.52 8.32 2.27s | 8.45s 8.32d 7.37d 7.72 7.31d 5.13d 4.04 3.51 3.02 3.38 3.66，3.22 7.26 7.78 7.48 8.23 2.33.2.31 | 8.32s 8.29 7.32 7.53d 6.85d 5.16d 4.26 3.67 3.59 3.16 4.14，3.52 7.32 7.79 7.52 8.27 2.25，1.79 |
Annotate: compd A, C solvent are (CD
3)
2CO, compd B solvent are CD
3OD
Table 2 compound (A, B, C)
13CNMR data (ppm)
| No. | A | B * | C |
| 2 3 4 5 6 7 8 9 10 1’ 2’，6’ 3’，5’ 4’ -CH 3 1” 2” | 152.9 123.9 174.7 125.8 122.5 152.6 121.4 154.7 121.1 123.6 129.7 114.7 157.0 19.7 73.2 72.6 | 153.1 125.3 177.5 127.7 123.5 156.0 125.5 156.0 122.7 125.1 131.5 122.9 130.9 21.0，21.0 75.0 74.2 | 153.0 123.6 174.7 125.9 122.6 152.5 121.4 154.7 120.9 123.9 129.8 114.6 157.0 19.7，19.3 73.2 72.5 |
| 3” 4” 5” 6” 1”’ 2”’ 3”’ 4”’ 5”’ 6”’ C＝O | 78.7 71.0 80.9 62.1 121.4 151.2 123.9 134.7 125.8 131.1 174.3，168.9 | 80.0 72.4 83.1 63.6 124.0 152.5 125.1 136.0 127.4 133.0 171.6，171.3 164.5 | 78.0 70.9 78.3 63.9 121.8 151.2 124.0 134.5 125.8 131.5 169.6，169.6 168.6 |
Annotate: compd A, C solvent are (CD
3)
2CO, compd B solvent are CD
3OD
2. the test of pesticide effectiveness:
Instrument: RYXN-96B multifunctional intellectual blood agglutometer, Shanghai General Machinery ﹠ Electric technology Inst.'s product;
Material: being tried blood plasma is provided by the healthy male youth volunteer; Adenosine diphosphate (ADP) (ADP), self-control 7-acetyl salicyloyl puerarin, other agents useful for same is analytical pure.
2.1 be subjected to the preparation of reagent thing solution
Precision takes by weighing acetylsalicylic acid (ASP), puerarin (Pur) and 7-acetyl salicyloyl puerarin respectively, makees solvent with 0.9%NaCl solution and is mixed with high density respectively and is tried solution (C
High≈ 36mmol.L
-1), middle concentration tried solution (C
In≈ 10mmol.L
-1) and lower concentration tried solution (C
Low≈ 3mmol.L
-1).
Acetylsalicylic acid and puerarin by waiting accurate weighing of molar ratio result calculated, are prepared the mixing solutions of high, medium and low three concentration identical with above-mentioned test solution concentration after the physical mixed.
With puerarin derivate solution is experimental group, acetylsalicylic acid, puerarin and etc. the mole mixing solutions be control group, measure and contain the hematoblastic aggregation rate of a certain amount of medicine blood plasma, estimate the drug action of medicine with the anticoagulant rate.
2.2 the preparation of blood plasma
Get blood 10ml with the young ulnar vein on an empty stomach of age group healthy male, insert 3.8% Sodium Citrate anticoagulant tube (blood and antithrombotics volume ratio are 9: 1).With the centrifugal 5min of 500r/min rotating speed, getting supernatant liquor is platelet rich plasma (PRP); With the centrifugal 10min of 3000r/min rotating speed, separated plasma obtains platelet poor plasma (PPP) then.Make blank adjusting instrument with platelet poor plasma.
2.3 medicine platelet aggregation-against experiment
Accurately pipette platelet rich plasma 200 μ l in the testing tube of blood agglutometer, adding is subjected to reagent thing solution 20 μ l (to make its final concentration in blood plasma be about C respectively
High3mmol.L
-1, C
In0.9mmol.L
-1And C
Low0.29mmol.L
-1).Electronic stirring 1min, behind 37 ℃ of constant temperature hatching 6min, (making final concentration is 4 μ mol.L to add ADP platelet aggregation inductor 20 μ l
-1).Behind turbidimetry for Determination adding platelet aggregation inductor ADP, the MA of blood plasma in 8min.All blood plasma samples must be finished the mensuration of aggregation rate in 2h.
All (x ± s) expression, the anticoagulant rate of same concentrations different experiments group is carried out statistical t check with the anticoagulant rate data of 7-acetyl salicyloyl puerarin corresponding concentration respectively with the anticoagulant rate with measured experimental data.
2.4 test-results:
2.4.1 7-acetyl salicyloyl puerarin is to the influence of the outer platelet aggregation effect of human body
The platelet aggregation rate experimental data of 7-acetyl salicyloyl puerarin and the platelet aggregation rate data of blank assay are carried out statistical procedures, to investigate the effect whether medicine has platelet aggregation-against.Data Processing in Experiment the results are shown in Table 1.
2.4.2 the evaluation of 7-acetyl salicyloyl puerarin antiplatelet aggregative activity
7-acetyl salicyloyl puerarin carries out the investigation of statistical significance to the experimental data of the antiplatelet aggregative activity of acetylsalicylic acid, puerarin and acetylsalicylic acid and puerarin mixing solutions under the restraining effect of platelet aggregation and the same experimental conditions.To determine the meaning of puerarin structural modification, tentatively understand and infer the mechanism of the platelet aggregation-against that puerarin derivate is possible to its pharmacodynamic change.Data Processing in Experiment the results are shown in table 2.
Table 1 7-acetyl salicyloyl puerarin is to the influence of the outer platelet aggregation effect of human body (n=5, x ± s)
| Group | Blood plasma final concentration (mmol.L -1) | Sample number n | Platelet aggregation rate (%) | Inhibiting rate (%) |
| Concentration group low concentration group in the control group high density group | 3.00 0.90 0.27 | 5 5 5 5 | 31.88±7.55 6.65±4.63* 13.79±3.56* 20.70± 7.32** | 79.17±13.88 51.76±11.05 35.07±7.48 |
* with control group (adding 0.9%NaCl) platelet aggregation rate t check P＜0.001 relatively
* and control group (adding 0.9%NaCl) platelet aggregation rate t check P＜0.05 relatively
Table 2 7-acetyl salicyloyl puerarin, acetylsalicylic acid and puerarin
To the influence of the outer platelet aggregation effect of human body (n=5, x ± s)
| Final concentration (the mmol.L of medicine in blood plasma -1) | 7-acetyl salicyloyl puerarin | Acetylsalicylic acid | Puerarin | Mixed solution (ASP+Pur) |
| 3.00 0.90 0.27 IC 50 | 79.17±13.88 56.86±1.26 35.07±7.48 0.91 | 38.40± 8.12*** 24.94± 10.35*** 6.81± 2.01*** 3.99 | 47.46± 9.4*** 17.01± 1.89*** 9.36± 1.90*** 3.18 | 67.41±17.18 26.50± 7.92*** 15.10± 3.97** |
The anticoagulant rate of the puerarin derivate of * * and same concentrations t check relatively: P＜0.001
The anticoagulant rate of the puerarin derivate of * and same concentrations t check relatively: P＜0.01
Claims (9)
1. the compound of following general formula (I):
Wherein:
R
1, R
2, R
3Be meant: hydrogen, ethanoyl or acetyl salicyloyl, and R
1, R
2, R
3In at least one is the acetyl salicyloyl, R
4, R
5Or R
6Be meant hydrogen.
2. according to the described compound of claim 1, wherein R
1, R
2Or R
3Be meant: ethanoyl or acetyl salicyloyl; R
4, R
5Or R
6Be meant hydrogen.
3. according to the described compound of claim 2, wherein R
1Or R
2Be meant: ethanoyl or acetyl salicyloyl; R
3, R
4, R
5Or R
6Be meant hydrogen.
4. according to the described compound of claim 2, wherein R
1Or R
3Be meant: ethanoyl or acetyl salicyloyl; R
2, R
4, R
5Or R
6Be meant hydrogen.
5. according to the described compound of claim 2, wherein R
1Be meant the acetyl salicyloyl; R
2, R
3, R
4, R
5Or R
6Be meant hydrogen.
6. the preparation method of the described compound of one of claim 1～5, this method steps is as follows:
(1) preparation of acetyl bigcatkin willow acyl chlorides: with acetylsalicylic acid and thionyl chloride by 1: 1～2 mixed in molar ratio, with the pyridine is solvent, reacts 2～3 hours in 60 ℃～80 ℃ oil baths, removes solvent under reduced pressure, get acetyl bigcatkin willow acyl chlorides, place anhydrous tetrahydro furan standby;
(2) preparation puerarin derivate: puerarin is dissolved in the alkaline anhydrous solvent, under condition of ice bath, above-mentioned acetyl bigcatkin willow acyl chlorides is pressed and puerarin 1～5: 1 mol ratio slowly joins in the alkaline anhydrous solution of puerarin, 20 ℃～35 ℃ reactions 1～2 hour, refluxed 2～3 hours, conventional filtration, concentrated, evaporate to dryness obtain acetyl salicyloyl puerarin derivate;
(3) separation and purification of puerarin derivate: adopt conventional silica gel column chromatography means, above-mentioned reaction is obtained acetyl salicyloyl puerarin derivate carry out separation and purification.
7. according to the preparation method of the described compound of claim 6, it is characterized in that the anhydrous tetrahydro furan solvent that the described alkaline anhydrous solvent of step (2) is a saturated potassium carbonate.
8. preparation method according to claim 6 is characterized in that, the mol ratio of step (2) described acetyl bigcatkin willow acyl chlorides and puerarin is 2～3: 1.
9. as the application of the described compound of one of claim 1～5 in the medicine of preparation platelet aggregation-against.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100360709A CN1314677C (en) | 2004-11-10 | 2004-11-10 | Acetyl salicyl puerarin derivatives and preparation method and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100360709A CN1314677C (en) | 2004-11-10 | 2004-11-10 | Acetyl salicyl puerarin derivatives and preparation method and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1634912A CN1634912A (en) | 2005-07-06 |
| CN1314677C true CN1314677C (en) | 2007-05-09 |
Family
ID=34845764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100360709A Active CN1314677C (en) | 2004-11-10 | 2004-11-10 | Acetyl salicyl puerarin derivatives and preparation method and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1314677C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101805332A (en) * | 2010-04-30 | 2010-08-18 | 西安力邦制药有限公司 | Preparation method and application of puerarin derivatives |
| CN105601625B (en) * | 2015-11-20 | 2018-05-25 | 西安交通大学 | A kind of preparation process of Puerarin C16H25NO2 |
| CN105732559B (en) * | 2016-03-10 | 2020-07-07 | 滨州医学院 | Engelhardin derivative and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1763030A (en) * | 2004-10-20 | 2006-04-26 | 香港赛马会中药研究院有限公司 | Puerarin derivate and medical usage thereof |
-
2004
- 2004-11-10 CN CNB2004100360709A patent/CN1314677C/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1763030A (en) * | 2004-10-20 | 2006-04-26 | 香港赛马会中药研究院有限公司 | Puerarin derivate and medical usage thereof |
Non-Patent Citations (1)
| Title |
|---|
| 葛根素衍生物的制备及其活性 杨若林 李娜 闵知大，中国药科大学学报，第2期 1999 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1634912A (en) | 2005-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1869683A (en) | Fingerprint atlas quality investigating method of ginkgo lactone material | |
| CN1314677C (en) | Acetyl salicyl puerarin derivatives and preparation method and use thereof | |
| CN1304396C (en) | Derivative of canthardin and preparation method | |
| CN105384745A (en) | Crown ether cyclic quinazoline compound, preparation method therefor and application thereof in preparing tumor therapy and imaging drug | |
| CN113616667A (en) | Nucleotide composition for adjuvant therapy of diabetes mellitus and preparation method and application thereof | |
| CN1530100A (en) | Food containing Angelica sinensis extractive and medicine composition thereof | |
| CN104940216A (en) | Application of galloyl-glucoside derivative and pharmaceutical composition for treating hyperuricemia | |
| CN111808117A (en) | Artemisinin-anilinoquinazoline D-type derivative, and pharmaceutical composition and application thereof | |
| CN102603847A (en) | Preparation method and medicinal application of ginsenoside Rh2 aliphatic ester compound | |
| CN105294641B (en) | Brefeldin A selenium ester derivant and its preparation and application | |
| CN101402667A (en) | Glycosylation modified nitric oxide donor type oleaolic acid compounds, preparation and uses thereof | |
| CN101805332A (en) | Preparation method and application of puerarin derivatives | |
| CN1479744A (en) | Crystalline glucosamine sulphate metal salts and its preparation method | |
| CN103301079B (en) | Capecitabine pharmaceutical composition and preparation method thereof | |
| CN102786687B (en) | Polyasparaginyl-L-cysteine and polyasparaginyl-L-methionine with polymerization degree of 59, preparation method and application thereof | |
| CN101293889B (en) | Water-soluble arteannuin derivative and preparation method thereof | |
| CN1686102A (en) | Application of cantharidin derivative in preparation of antitumour medicine | |
| CN102786458B (en) | Pyrrole formamide derivative, and preparation method and application thereof | |
| CN102850364B (en) | Indian apple derivative and composition thereof, preparation method and application | |
| CN1785216A (en) | Medicinal composition contg. total ginkgo flavone, its prepn. method and use | |
| CN1768753A (en) | Medicinal composition containing bilobalide B and its preparation process and usage | |
| CN1718183A (en) | Neo-garcinolic acid prepn. for injection use, prepn. method and use thereof | |
| CN113845483B (en) | Pink back pteridonic acid and 5-fluorouracil hybrid, preparation method and application thereof | |
| CN1307182C (en) | Preparation of bromo-dihydroartemisine | |
| CN104672191B (en) | Caulis Seu Folium Lespedezae Bicoloris phenol E1Class compound and preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: RUIYANG PHARMACY CO., LTD. Free format text: FORMER OWNER: SHANDONG UNIV. Effective date: 20091120 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20091120 Address after: No. 6 Erlang Road, Yiyuan County, Shandong, Zibo Patentee after: Reyoung Pharmaceutical Co., Ltd. Address before: No. 44, Wenhua West Road, Lixia District, Shandong, Ji'nan Patentee before: Shandong University |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 256100 No. 6 Erlang Road, Yiyuan County, Shandong, Zibo Patentee after: Ruiyang Pharmaceutical Co., Ltd Address before: 256100 No. 6 Erlang Road, Yiyuan County, Shandong, Zibo Patentee before: REYOUNG PHARMACEUTICAL Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |